文献速递糖尿病

2型糖尿病中基于模型参数的β细胞功能对治疗的不同反应:GRADE研究结果

Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2025-01-01

在GRADE研究中,4712例2型糖尿病成人随机接受甘精胰岛素、格列美脲、利拉鲁肽或西格列汀联合二甲双胍治疗,用口服葡萄糖耐量试验数学模型评估β细胞功能参数。各治疗第1年参数不同程度升高,随后均下降;利拉鲁肽升幅最大且研究结束时仍高于基线。参数较高者血糖恶化风险较低,但治疗未改变该关联。

要点

  • 利拉鲁肽使胰岛素分泌率、葡萄糖敏感性和增强效应升幅最大,研究结束时仍高于基线。
  • 西格列汀改善葡萄糖敏感性,对其他参数影响有限;格列美脲短暂升高分泌率和速率敏感性。
  • β细胞功能参数较高者血糖失败风险较低,但治疗未改变参数与血糖结局的关联。

核心结论

  • 常用降糖药物对2型糖尿病β细胞功能的不同生理组分产生不同影响;无论治疗方式如何,较低的β细胞功能与早期血糖失败相关,且β细胞功能在初始改善后逐渐下降。

研究设计与样本

  • GRADE研究纳入4712例2型糖尿病成人,随机接受甘精胰岛素、格列美脲、利拉鲁肽或西格列汀联合基线二甲双胍治疗,在基线及随机后1、3、5年用口服葡萄糖耐量试验数学模型评估β细胞功能参数。
  • 采用线性混合效应模型比较各治疗间变化,用Cox比例风险模型和分类与回归树(CART)分析评估模型参数与血糖失败(A1C>7.5%;58.5 mmol/mol)的关联。

主要发现

  • 各治疗第1年β细胞功能参数不同程度升高,随后所有治疗均下降,变化有统计学显著性。
  • 利拉鲁肽使胰岛素分泌率、葡萄糖敏感性和增强效应升幅最大,研究结束时仍高于基线。
  • 西格列汀改善葡萄糖敏感性,对其他参数影响有限;格列美脲短暂升高胰岛素分泌率和速率敏感性,对葡萄糖敏感性和增强效应影响很小;甘精胰岛素使速率敏感性升幅最大。
  • β细胞功能参数较高对血糖恶化有保护作用,但治疗未改变这些参数与血糖结局的关系。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell function parameters derived from mathematical modeling of oral glucose tolerance tests were assessed at baseline (N = 4,712) and 1, 3, and 5 years following randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin. Parameters included insulin secretion rate (ISR), glucose sensitivity (insulin response to glucose), rate sensitivity (early insulin response), and potentiation. Linear mixed-effects models were used to compare changes across treatments. With Cox proportional hazards and Classification And Regression Tree (CART) analyses we evaluated associations between model parameters and glycemic failure (A1C >7.5%; 58.5 mmol/mol). RESULTS: β-Cell function parameters increased variably at year 1 across treatments but subsequently declined for all treatments. Statistically significant changes were noted. Liraglutide led to the greatest increases in ISR, glucose sensitivity and potentiation, remaining above baseline at study end. Sitagliptin improved glucose sensitivity, with modest effects on other parameters. Glimepiride temporarily increased ISR and rate sensitivity but minimally increased glucose sensitivity or potentiation. Rate sensitivity increased most with glargine. Higher β-cell function parameters were protective against glycemic deterioration, but treatment did not alter the relationship between these parameters and glycemic outcomes. CONCLUSIONS: Common glucose-lowering medications impact different physiologic components of β-cell function in T2D. Regardless of treatment modality, lower β-cell function associated with early glycemic failure, and β-cell function progressively declined after initial improvement.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Utzschneider KM, Tripputi M, Butera NM, et al. Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025. PMID: 39998948. doi:10.2337/dc24-2419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。